SANGAMO THERAPEUTICS, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SANGAMO THERAPEUTICS, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $13.08M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $11.81M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $8.25M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $3.43M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $8.92M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $2.82M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $3.70M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $3.94M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $9.12M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $8.57M | Feb 28, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.55M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $57.80M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $176.23M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $111.30M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $110.70M | Mar 13, 2024 |
| FY2020 | Dec 31, 2020 | $25.80M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $57.76M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $21.55M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $13.08M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $54.85M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($122.93M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($97.94M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($257.83M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($192.28M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | ($178.29M) | Mar 13, 2024 |
| FY2020 | Dec 31, 2020 | ($40.60M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($1.55M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($35.93M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($42.91M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $4.56M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.24M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($103.97M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($274.01M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($201.28M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | ($183.34M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | ($129.55M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($105.18M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($77.15M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($56.36M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($72.56M) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.67M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $111.52M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $234.06M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $249.90M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $230.82M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $180.65M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $145.92M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $114.87M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $65.73M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $65.62M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($97.21M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($67.14M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($224.84M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($223.63M) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | ($233.25M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $169.88M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($144.40M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $36.55M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $11.18M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | ($65.88M) | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $267.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $21.16M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $20.17M | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | $23.28M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $14.71M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $20.68M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $43.07M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.75M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $732.0K | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.75M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $101.64M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $165.32M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $562.51M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $721.92M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $938.55M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $637.52M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $590.40M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $286.74M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $157.89M | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.01M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $78.87M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $82.43M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $267.55M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $346.58M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $441.18M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $204.78M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $223.14M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $98.84M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $21.70M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.27M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.77M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $82.89M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $294.96M | Mar 17, 2025 |
| FY2021 | Dec 31, 2021 | $375.34M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $498.23M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $432.55M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $366.52M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $187.90M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $136.20M | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 17, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Mar 17, 2025 |
| FY2024 | Dec 31, 2022 | $37.55M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $39.70M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $42.80M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $39.27M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $40.04M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.59M | Feb 28, 2020 |
| FY2017 | Dec 31, 2016 | $1.59M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $1.59M | Feb 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.63B) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($1.50B) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($1.41B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.15B) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($956.27M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($777.98M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($656.99M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($562.70M) | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | ($495.48M) | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | ($440.91M) | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.95M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $41.92M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $45.20M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $100.44M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $178.87M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $131.33M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $80.43M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $140.42M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $49.83M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $22.06M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 13, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 350.69M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 212.84M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 178.13M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 166.79M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 145.92M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 142.06M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 115.97M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 102.19M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 85.60M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 70.87M | Mar 1, 2018 |